<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01909336</url>
  </required_header>
  <id_info>
    <org_study_id>SIvsSHnh</org_study_id>
    <nct_id>NCT01909336</nct_id>
  </id_info>
  <brief_title>Use of Isotonic Solutions Versus Hypotonic Solutions for Preventing Hospital Acquired Hyponatremia</brief_title>
  <official_title>Use of Isotonic Solutions Versus Hypotonic Solutions for Preventing Hospital Acquired Hyponatremia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Tecnologico y de Estudios Superiores de Monterey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tecnologico de Monterrey</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Tecnologico y de Estudios Superiores de Monterey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if isotonic solutions reduce the risk of hospital
      acquired hyponatremia compared with hypotonic solutions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, Randomized, Controlled clinical trial.

      The purpose of this study is to determine if isotonic solutions reduce the risk of hospital
      acquired hyponatremia compared with hypotonic solutions

      This study will include 150 patients in 2 groups according to these type of pathology: group
      1: medical conditions which includes respiratory problems (pneumonia, bronchiolitis, acute
      asthma attack) and acute gastrointestinal problems (bacterial or viral gastroenteritis) and
      group 2: surgical conditions (pre, peri or postoperative patients will be included). Each
      group will be randomized to receive 3 types of interventions: 0.3% Saline (hypotonic
      solution), 0.45% Saline (hypotonic solution) or 0.9% Saline (isotonic solution). In
      non-dehydrated patients the daily total volume of liquid infused will be determined by the
      volumetric Holliday- Segar* formula and the daily total volume will be calculated by adding
      the maintenance requirements (using the Holliday Segar formula) to the fluid deficit
      (according to percent of estimated weight**) in dehydrated patients.

      The glucose concentrations in the first group will be 3.3%, and in group 2 and 3 will be 5%.
      The potassium concentration will be 20mEq/L in all groups. Blood samples will be collected
      before, 8 hours and 24 hours after the start of intravenous fluid, for the analysis of
      sodium, potassium, glucose, urea and creatinine. The adverse clinical outcomes at 8 and 24
      hours of the start of intravenous fluid will also be recorded. The sodium plasma level, the
      incidence of hyponatremia and the adverse clinical outcomes will be compared.

      *0-10 kilogram (kg): 100ml/kg per day; 10-20 kg: 1000 ml + 50 ml/kg/day over 10 kg; &gt;20 kg:
      1500 ml + 20ml/ kg over 20kg

      ** In patients under 10 kg correspond to a loss of 5% (50 mL/kg) in mild dehydration and 10%
      in moderate dehydration. In 10 kg or more: 3% (30 mL/kg) in mild dehydration and 6% (60
      mL/kg) in moderate dehydration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital Acquired Hyponatremia</measure>
    <time_frame>8 hours</time_frame>
    <description>Serum sodium less than 135 mEq/L at 8 hours in a patient with normal serum sodium (135 mEq/L to 145mEq/L) at the beginning of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dysnatraemias at T8</measure>
    <time_frame>8 hours</time_frame>
    <description>hyponatraemia (defined as serum sodium &lt; 135 mmol/L), normonatremia (defined as serum sodium 135-145 mmol/L) or hypernatraemia (defined as serum sodium &gt; 145 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Reactions Attributed to Acute Plasma Sodium Changes</measure>
    <time_frame>8 hours</time_frame>
    <description>Adjudicated Morbidity Attributed to Acute Plasma Sodium Changes assessed at 8 hours</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Hyponatremia</condition>
  <arm_group>
    <arm_group_label>Group 1: 0.3% Saline in 3.3% dextrose (intravenous)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1: 0.3% Saline in 3.3% dextrose (intravenous)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: 0.45% Saline in 5% dextrose (intravenous)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2: 0.45% Saline in 5% dextrose (intravenous)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: 0.9% Saline in 5% dextrose (intravenous)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 3: 0.9% Saline in 5% dextrose (intravenous)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3% Saline in 3.3% dextrose</intervention_name>
    <description>Hypotonic Solutions: 0.3% Saline in 3.3% dextrose</description>
    <arm_group_label>Group 1: 0.3% Saline in 3.3% dextrose (intravenous)</arm_group_label>
    <other_name>Hypotonic Solutions: 0.3% Saline + 3.3% dextrose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.45% Saline in 5% dextrose</intervention_name>
    <description>Hypotonic Solutions: 0.45% Saline in 5% dextrose</description>
    <arm_group_label>Group 2: 0.45% Saline in 5% dextrose (intravenous)</arm_group_label>
    <other_name>Hypotonic Solutions: 0.45% Saline in 5% dextrose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Saline in 5% dextrose</intervention_name>
    <description>Isotonic Solutions 0.9% Saline in 5% dextrose</description>
    <arm_group_label>Group 3: 0.9% Saline in 5% dextrose (intravenous)</arm_group_label>
    <other_name>Isotonic Solutions 0.9% Saline in 5% dextrose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children between 3 months to 15 years.

          -  Need for intravenous fluids for 8 hours or more.

          -  Normal serum sodium at the beginning of the study of the study (135-145 mEQ/L).

          -  Acute respiratory problems (acute asthma attack, bronchiolitis or pneumonia).

          -  Acute gastrointestinal disorders (viral o bacterial gastroenteritis).

          -  Elective surgical procedures.

          -  Pre, peri o post operative patients (acute appendicitis, intussusception, intestinal
             perforation, ileus).

        Exclusion Criteria:

          -  Severe hyponatremia (serum sodium &lt; 125 mEq/L).

          -  Severe hypernatremia (serum sodium &gt;155 mEq/L).

          -  Need for intravenous fluids for less than 8 hours according with their treating
             physician.

          -  Severe dehydration or Shock.

          -  Preexisting chronic diseases (renal diseases, heart diseases or endocrine disorders).

          -  Neurologic diseases.

          -  Head trauma.

          -  Cerebral edema or Intracranial hypertension.

          -  Diabetic ketoacidosis.

          -  Use of diuretics one week or less before the study.

          -  Need for admission to the pediatric critical intensive care unit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Montserrat Flores Robles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tecnologico de Monterrey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Alberto Cuello García, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centro de Medicina Basada en Evidencias, Escuela de Medicina y Ciencias de la Salud, Tecnológico de Monterrey.</affiliation>
  </overall_official>
  <reference>
    <citation>Moritz ML, Ayus JC. Hospital-acquired hyponatremia--why are hypotonic parenteral fluids still being used? Nat Clin Pract Nephrol. 2007 Jul;3(7):374-82. Review.</citation>
    <PMID>17592470</PMID>
  </reference>
  <reference>
    <citation>Choong K, Kho ME, Menon K, Bohn D. Hypotonic versus isotonic saline in hospitalised children: a systematic review. Arch Dis Child. 2006 Oct;91(10):828-35. Epub 2006 Jun 5. Review.</citation>
    <PMID>16754657</PMID>
  </reference>
  <reference>
    <citation>Montañana PA, Modesto i Alapont V, Ocón AP, López PO, López Prats JL, Toledo Parreño JD. The use of isotonic fluid as maintenance therapy prevents iatrogenic hyponatremia in pediatrics: a randomized, controlled open study. Pediatr Crit Care Med. 2008 Nov;9(6):589-97. doi: 10.1097/PCC.0b013e31818d3192.</citation>
    <PMID>18838929</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2013</study_first_submitted>
  <study_first_submitted_qc>July 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2013</study_first_posted>
  <results_first_submitted>August 29, 2016</results_first_submitted>
  <results_first_submitted_qc>October 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 16, 2016</results_first_posted>
  <last_update_submitted>October 21, 2016</last_update_submitted>
  <last_update_submitted_qc>October 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Tecnologico y de Estudios Superiores de Monterey</investigator_affiliation>
    <investigator_full_name>Claudia Montserrat Flores Robles, MD</investigator_full_name>
    <investigator_title>Claudia Montserrat Flores Robles</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This trial was conducted in the paediatric and emer- gency departments of the Hospital Regional Materno Infantil de Alta Especialidad in Nuevo Leon, Mexico between August 2013 and February 2014.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: 0.3% Saline in 3.3% Dextrose (Intravenous)</title>
          <description>Group 1: 0.3% Saline in 3.3% dextrose (intravenous): Hypotonic Solutions</description>
        </group>
        <group group_id="P2">
          <title>Group 2: 0.45% Saline in 5% Dextrose (Intravenous)</title>
          <description>Group 2: 0.45% Saline in 5% dextrose (intravenous): Hypotonic Solutions</description>
        </group>
        <group group_id="P3">
          <title>Group 3: 0.9% Saline in 5% Dextrose (Intravenous)</title>
          <description>Group 3: 0.9% Saline in 5% dextrose (intravenous): Isotonic Solutions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: 0.3% Saline in 3.3% Dextrose (Intravenous)</title>
          <description>Group 1: 0.3% Saline in 3.3% dextrose (intravenous)
0.3% Saline in 3.3% dextrose: Hypotonic Solutions: 0.3% Saline in 3.3% dextrose</description>
        </group>
        <group group_id="B2">
          <title>Group 2: 0.45% Saline in 5% Dextrose (Intravenous)</title>
          <description>Group 2: 0.45% Saline in 5% dextrose (intravenous)
0.45% Saline in 5% dextrose: Hypotonic Solutions: 0.45% Saline in 5% dextrose</description>
        </group>
        <group group_id="B3">
          <title>Group 3: 0.9% Saline in 5% Dextrose (Intravenous)</title>
          <description>Group 3: 0.9% Saline in 5% dextrose (intravenous)
0.9% Saline in 5% dextrose: Isotonic Solutions 0.9% Saline in 5% dextrose</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="151"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="56.1"/>
                    <measurement group_id="B2" value="54.6" spread="55.9"/>
                    <measurement group_id="B3" value="58.8" spread="57.7"/>
                    <measurement group_id="B4" value="58.9" spread="56.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dehydration (mild), n</title>
          <description>Dry mucous membranes in association with normal hemodynamic measurements</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure, mmHg</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101.1" spread="11.2"/>
                    <measurement group_id="B2" value="99.4" spread="9"/>
                    <measurement group_id="B3" value="99.8" spread="11.4"/>
                    <measurement group_id="B4" value="100.1" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart rate, bpm</title>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124" spread="25"/>
                    <measurement group_id="B2" value="126" spread="29"/>
                    <measurement group_id="B3" value="128" spread="28"/>
                    <measurement group_id="B4" value="126" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum sodium, mmol/L</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135" spread="2.8"/>
                    <measurement group_id="B2" value="135.8" spread="3.1"/>
                    <measurement group_id="B3" value="135.8" spread="3.2"/>
                    <measurement group_id="B4" value="135.5" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum osmolarity, mOsm/L</title>
          <units>mOsm/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="277.4" spread="10.6"/>
                    <measurement group_id="B2" value="278" spread="16.2"/>
                    <measurement group_id="B3" value="281.4" spread="9.5"/>
                    <measurement group_id="B4" value="279" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Normonatremic, n</title>
          <description>defined as serum sodium 135-145 mmol/L</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hyponatraemia, n</title>
          <description>defined as serum sodium &lt; 135 mmol/L.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypernatremic, n</title>
          <description>defined as serum sodium &gt; 145 mmol/L.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hospital Acquired Hyponatremia</title>
        <description>Serum sodium less than 135 mEq/L at 8 hours in a patient with normal serum sodium (135 mEq/L to 145mEq/L) at the beginning of the study</description>
        <time_frame>8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 0.3% Saline in 3.3% Dextrose (Intravenous)</title>
            <description>Group 1: 0.3% Saline in 3.3% dextrose (intravenous): Hypotonic Solutions</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 0.45% Saline in 5% Dextrose (Intravenous)</title>
            <description>Group 2: 0.45% Saline in 5% dextrose (intravenous): Hypotonic Solutions</description>
          </group>
          <group group_id="O3">
            <title>Group 3: 0.9% Saline in 5% Dextrose (Intravenous)</title>
            <description>Group 3: 0.9% Saline in 5% dextrose (intravenous): Isotonic Solutions</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Acquired Hyponatremia</title>
          <description>Serum sodium less than 135 mEq/L at 8 hours in a patient with normal serum sodium (135 mEq/L to 145mEq/L) at the beginning of the study</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dysnatraemias at T8</title>
        <description>hyponatraemia (defined as serum sodium &lt; 135 mmol/L), normonatremia (defined as serum sodium 135-145 mmol/L) or hypernatraemia (defined as serum sodium &gt; 145 mmol/L)</description>
        <time_frame>8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 0.3% Saline in 3.3% Dextrose (Intravenous)</title>
            <description>Group 1: 0.3% Saline in 3.3% dextrose (intravenous): Hypotonic Solutions</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 0.45% Saline in 5% Dextrose (Intravenous)</title>
            <description>Group 2: 0.45% Saline in 5% dextrose (intravenous): Hypotonic Solutions</description>
          </group>
          <group group_id="O3">
            <title>Group 3: 0.9% Saline in 5% Dextrose (Intravenous)</title>
            <description>Group 3: 0.9% Saline in 5% dextrose (intravenous): Isotonic Solutions</description>
          </group>
        </group_list>
        <measure>
          <title>Dysnatraemias at T8</title>
          <description>hyponatraemia (defined as serum sodium &lt; 135 mmol/L), normonatremia (defined as serum sodium 135-145 mmol/L) or hypernatraemia (defined as serum sodium &gt; 145 mmol/L)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normonatremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyponatremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypernatremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Reactions Attributed to Acute Plasma Sodium Changes</title>
        <description>Adjudicated Morbidity Attributed to Acute Plasma Sodium Changes assessed at 8 hours</description>
        <time_frame>8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 0.3% Saline in 3.3% Dextrose (Intravenous)</title>
            <description>Group 1: 0.3% Saline in 3.3% dextrose (intravenous): Hypotonic Solutions</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 0.45% Saline in 5% Dextrose (Intravenous)</title>
            <description>Group 2: 0.45% Saline in 5% dextrose (intravenous): Hypotonic Solutions</description>
          </group>
          <group group_id="O3">
            <title>Group 3: 0.9% Saline in 5% Dextrose (Intravenous)</title>
            <description>Group 3: 0.9% Saline in 5% dextrose (intravenous): Isotonic Solutions</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Reactions Attributed to Acute Plasma Sodium Changes</title>
          <description>Adjudicated Morbidity Attributed to Acute Plasma Sodium Changes assessed at 8 hours</description>
          <units>Minor Adverse Reactions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1: 0.3% Saline in 3.3% Dextrose (Intravenous)</title>
          <description>Group 1: 0.3% Saline in 3.3% dextrose (intravenous): Hypotonic Solutions</description>
        </group>
        <group group_id="E2">
          <title>Group 2: 0.45% Saline in 5% Dextrose (Intravenous)</title>
          <description>Group 2: 0.45% Saline in 5% dextrose (intravenous): Hypotonic Solutions</description>
        </group>
        <group group_id="E3">
          <title>Group 3: 0.9% Saline in 5% Dextrose (Intravenous)</title>
          <description>Group 3: 0.9% Saline in 5% dextrose (intravenous): Isotonic Solutions</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Claudia Montserrat Flores Robles</name_or_title>
      <organization>HIMFG</organization>
      <phone>(52) 5566756686</phone>
      <email>montseflores@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

